Human papillomavirus (HPV) Vaccine:
New Research has found that the Human papillomavirus (HPV) vaccine (Cervarix) reduces the risk of Cervical Cancer significantly in women.
- The results are important because the vaccine was introduced in the 2000s and studies confirming that it is effective against cancer have come up only recently.
- The Human papillomavirus (HPV) vaccine reduced cervical cancer cases by 87% among women in the U.K. who received the vaccine when they were 12 or 13 years old.
- It reduced the risk by 34% in women who were aged 16-18 years when they were offered the jab.
- Over a period of 11 years (since 2006), the vaccine prevented around 450 cervical cancers and around 17,200 cases of precancerous conditions.
- It is a type of cancer that occurs in the cells of the cervix – the lower part of the uterus that connects to the vagina.
- Various strains of the Human papillomavirus (HPV) play a role in causing most cervical cancer.
- When exposed to HPV, the body’s immune system typically prevents the virus from doing harm. In a small percentage of people, however, the virus survives for years, contributing to the process that causes some cervical cells to become cancer cells.
- The HPV vaccine (Cervarix) protects against two of the cancer-causing strains, which are HPV 16 and 18.
- Human papillomavirus (HPV) is the most common viral infection of the reproductive tract.
- There are more than 100 types of HPV.
- More than 40 types of HPV are spread through direct sexual contact.
- Out of these 40, two cause genital warts, while about a dozen of HPV cause different types of cancer including cervical, anal, oropharyngeal, penile, vulvar and vaginal.